anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Acute acquired concomitant esotropia (AACE) belongs to the category of concomitant strabismus. It is characterized by sudden onset, often accompanied by diplopia, and no change in the strabismus angle of each eye position. In recent years, with the increase in the use of smartphones and other screen devices, the incidence of AACE has been on the rise. Commonly used treatments in clinical practice include surgical treatment, botulinum toxin injection into the medial rectus muscle, and prism treatment. Patients with large-angle esotropia generally require surgical intervention to fundamentally correct patients eye positions and eliminate diplopia. However, surgical treatment requires waiting for six months in order to performed after the strabismus degree is stable. There are also risks of intraoperative trauma and secondary surgery. Patients with early and small-angle esotropia often choose prism treatment.

The principle of prism treatment is light refraction. After light is refracted through a prism, it falls on the fovea of the strabismic eye, eliminating diplopia. In the treatment of AACE, the main target population of prisms is patients with mild strabismus (the strabismus angle is usually less than 25 PD) (Wu et al., 2022). Wearing prisms can eliminate diplopia and relieve related symptoms, but it does not really correct the strabismus problem.

The high incidence of AACE is related to excessive close work and use of electronic products. Excessive close eye use can lead to accommodative dysfunction. Studies have found that AACE patients have abnormal accommodative function (Tong et al., 2020; Herlihy et al., 2013; Kemmanu et al., 2012; Lee et al., 2016). The accommodative function of AACE patients is weaker than normal, and the accommodation convergence to accommodation (AC/A) ratio is higher than normal (Tong et al., 2020). During clinical diagnosis and treatment, the accommodative function of AACE patients was examined and it was found that there was indeed abnormal accommodative function. Based on scientific research findings and the actual basis of clinical practice, improving accommodative function through accommodative training may be a good treatment option for early and small-angle AACE patients. However, existing studies have not fully explored the effectiveness and safety of accommodative exercise in the treatment of small-angle AACE, and there has been no study comparing the therapeutic outcomes of accommodative training and prism treatment on small-angle AACE.

In order to better guide clinical practice, we conducted a randomized controlled study to objectively evaluate and compare the therapeutic effects of accommodative training and prism therapy on AACE. It is expected that the research results will provide more treatment options for AACE patients and provide important guidance for clinical selection of appropriate methods to treat small-angle AACE.
The invention relates to a method for producing a biologically active and specifically acting substance from vegetable raw material for preventing and treating pathologic cases. The green parts of wild graminyceous Graminea family and Calamagrostis Anans and Deschampsia Beauv genus plants are used in the form of a vegetable raw material. Said graminyceous plants are picked up during a period from a culming to the heading up, separately dried to a moisture content of 8-20 % and are mixed at the following component ratio:   80-20 mass % Calamagrostis Adans   20-80 mass % Deshampsia Beauv. Afterwards, liquid water-soluble fractions are separated from said vegetable raw material by extraction thereof with the aid of ethyl alcohol at a mass ratio between the raw material and alcohol of 1:1-1:10 associated with a simultaneous periodical control of a dry residue mass index. When he value of said index reaches 0.5-1.5 %, the extraction is stopped and solid impurities are removed from rare fractions by filtering with the aid of a loose filter as far as a finished product is obtained. The extraction of said liquid water-soluble fractions from the vegetable raw material is carried out by a maceration and/or remaceration method at a temperature of 18-47 °C using a 90-99.8 %ethyl alcohol.
FIELD: veterinary science, virology. SUBSTANCE: invention relates to method of preparing living vaccine, method of immunization of pigs against porcine reproductive and respiratory syndrome (PRRS) and, essentially, to isolated and purified virus strain ATCC VR 2509. Vaccine is administrated in sows, gilts and piglets for their immunization against PRRS. Vaccine comprises living strain of virus VR 2509 that is avirulent and induces effective immunity. Vaccine has to contain about from 10 4  to 10 8  plaque-forming virus units that ensures to obtain optimal result in animals immunization. EFFECT: improved method of vaccine preparing, enhanced effectiveness, valuable curative properties. 14 cl, 3 dwg, 4 tbl, 3 ex
An example method includes receiving multiple spectrometer scans of a sample obtained from a person. A spectrometer scan includes intensities of wavelengths of light in a range of wavelengths. The light has passed through at least a portion of the sample. For multiple wavelengths of light in the range of wavelengths, a particular profile intensity utilizing particular intensities of wavelengths of light included in the multiple spectrometer scans is calculated to obtain multiple profile intensities. Slopes of the multiple profile intensities at multiple wavelengths are calculated to obtain a set of slopes. A fitting function is applied to the set of slopes to obtain a set of values. A set of decision trees is applied to the set of values to obtain a result. The result indicates either a positive pathogen detection or a negative pathogen detection for the sample. A pathogen detection notification is generated indicating either the positive pathogen detection or the negative pathogen detection for the sample. The pathogen detection notification is provided.
PURPOSE: In 2010, the US Food and Drug Administration approved eribulin for the treatment of metastatic breast cancer (MBC). Since then, the treatment landscape has evolved with many new therapy classes, a more recent one being the small molecule inhibitors of phosphoinositide 3 kinase (PI3K). We sought to characterize the treatment patterns and clinical outcomes of patients with MBC who received eribulin following prior treatment with a PI3K inhibitor.
METHODS: A retrospective cohort study based on medical record review included MBC patients who initiated eribulin between March 2019 and September 2020 following prior treatment with a PI3K inhibitor was conducted. Patient demographics, treatment characteristics, and clinical outcomes were analyzed descriptively. Real-world progression-free survival (rwPFS) and overall survival (OS) were estimated from the initiation of eribulin therapy using Kaplan-Meier analyses.
RESULTS: 82 eligible patients were included. Patients' median age at eribulin initiation was 62 years; 86.5% had hormone receptor-positive, human epidermal growth factor receptor 2-negative tumors. Eribulin was most often administered in the second or third line (82.9%) in the metastatic setting. Best overall response on eribulin was reported as complete or partial response in 72% of the patients. The median rwPFS was 18.9 months (95% confidence interval [CI], 12.4-not estimable); median OS was not reached. The estimated rwPFS and OS rates at 12 months were 63.3% (95% CI, 50.5-73.7) and 82.6% (95% CI, 72.4-89.3), respectively.
CONCLUSION: Our real-world study suggests that eribulin may be a potential treatment option for MBC patients who fail a prior PI3K inhibitor.
This is a 2-arm randomized controlled trial to test the effects of hookah tobacco public education messages among young adults who are susceptible non-users of hookah tobacco and current hookah tobacco users. Primary outcomes of hookah use behavior will be measured at the 6-month follow-up assessment. Secondary outcomes include curiosity to use hookah tobacco among susceptible non-users and motivation to quit using hookah tobacco among current users. All outcomes are also assessed at 2- and 4-month follow-up time points. All trial participants will be recruited from a US national consumer research panel. Eligible participants will be 1) young adults ages 18 to 30 (inclusive); 2) who have never used hookah tobacco but are deemed susceptible or report hookah tobacco use at least once within the past month; and 3) are enrolled members of the partnering consumer research panel. Panel members will be contacted via email with a brief description of the study and a link to an eligibility screener and online informed consent form. Eligible participants will complete a secure online baseline assessment of demographic characteristics, tobacco use history, and measures of hookah tobacco use behavior, beliefs, attitudes, and perceptions. After completing a baseline, participants will be randomly assigned in approximately equal numbers to one of two arms: 1) hookah tobacco messaging arm; 2) control arm. Through 4 brief study communications delivered approximately weekly, participants will receive study messages to which they are randomized and will complete brief self-report measures online on their responses to the messages. For the hookah tobacco messaging arm, communications will consist of study messages conveying risks of hookah tobacco use with random assignment of the order of messages with each exposure. In response to each message, participants will complete measures of message response and hookah-related beliefs, attitudes, and perceptions. Participants in the control condition will receive study communications with brief messages about health behaviors unrelated to tobacco (e.g., sun protection) and will complete the same measures. Hookah tobacco use behaviors, intentions and curiosity to use hookah tobacco (non-users), motivation to quit (current users), and hypothesized mediators will be assessed 2-, 4-, and 6-months after the message exposure period with the primary outcomes captured at 6-month follow-up.
Nalbuphine hydrochloride injection (80mg) plus 0.9% saline are combined into 80 ml self-controlled analgesic pump, which will be run 25minutes before ablation under Electrocardiogram monitoring. Single pressure administration if numerical rating scale≥4 points.
Adopts an artificial intelligent disease diagnosis system and method; the method comprises the following steps: intelligent terminal, communication device, peripheral equipment, memory cell, intelligent unit, main control unit. The user uses the intelligent terminal, uses the inquiry of multi-media, many picture formats, and is more accurate more fast than the text or pronunciation inquiry, and the user understands the subject. And self-learning software is provided, and the performance is self-perfected. The excellent performance of intelligent inquiry far exceeds the in-situ inquiry and remote inquiry of doctors. And the disease diagnosis software compares and identifies the inquiry conclusion with the parameters of a plurality of cases, diagnoses the diseases of the user and obtains a disease diagnosis report. The estimated accuracy rate can be increased in the disease diagnosis report. The intelligent diagnosis of diseases, which subverts the tradition, uses artificial intelligence to diagnose serious diseases and dangerous diseases in real time. The system is convenient for vast users to diagnose diseases quickly and timely, and is an indispensable assistant for entity hospitals, health management centers, online hospitals and unmanned hospitals.
Approximately 8 subjects with mild or severe hepatic impairment will receive 6 mg of daprodustat as a single oral dose in the fasted state. This group will include at least one subject with a Child-Pugh score of 5 and one with a score of 6 for mild hepatic impairment and at least one subject with a Child-Pugh score of 10 or 11 and one with a score of 12 or 13 for severe hepatic impairment. The group will also include at least one female and at least one male subject.
Extranodal natural killer/T-cell lymphoma (ENKTCL), nasal type, is a rare subtype of non-Hodgkin lymphoma (NHL) with relatively high incidence in China. Radiotherapy alone for stage IE/IIE diseases has good response rate but with high relapse rates, ranging from 20-50%. The combination of chemotherapy and radiotherapy improved the long-term survival for patients with stage IE/IIE diseases. But the optimal treatment schedule has not been established. This study is designed with four cycles CAPA induction immunotherapy, followed by 50-56Gy radiotherapy as an approach for stage IE/IIE ENKTCL. The efficacy and safety of this treatment will be measured.
Recently, the opioid epidemic has been the center of focus for healthcare providers and governmental agencies due to rising rates of opioid abuse, opioid-related fatalities, and overall economic burden of treating the opioid epidemic. The prescribing patterns of opioid pain medications have fallen under scrutiny and healthcare providers have sought alternative pain management strategies that have limited opioid pain medication use. As orthopaedic surgeons account for 7.7% of all dispensed opioid prescriptions within the United States, surgeons have investigated multimodal pain management strategies to assess effectiveness in controlling postoperative pain as well as limiting opioid use and opioid related complications. The literature documents the safety and effectiveness of non-steroid anti-inflammatory drugs (NSAID) and acetaminophen in soft tissue hand procedures and distal radius fracture plating. Currently, there remains no clear consensus on the ideal pain management strategy following open reduction internal fixation (ORIF) of distal radius fractures and the vast majority of strategies are based on opiate-driven protocols. This study will investigate the effectiveness of an opiate sparing protocol following open reduction and internal fixation (ORIF) of distal radius fractures on opiate consumption as measured by oral morphine equivalents at the 2, 6 and 12 week postoperative time point through collection of pill counts. Secondary outcomes are pain scores, patient satisfaction, and safety reporting (complications, reoperations, and readmissions) during the 12-week episode-of-care. This study will document the safety and effectiveness of an opiate sparing, multimodal pain management protocol in properly selected patients undergoing ORIF of distal radius fractures.

Following written consent documentation, Subjects will be randomized to either the opiate sparing cohort or the opiate based cohort at a 1:1 randomization. No blinding will occur as part of the study.
Provided is an application of a composition of a prebiotic and a probiotic in preparation of food or medicine. The prebiotic comprises a human milk oligosaccharide. The probiotic comprises Bifidobacterium longum subsp. infantis. The food or medicine is food or medicine having at least one of the following functions: enhancing the defense of organisms against Staphylococcus aureus infection; improving the innate immunity of organisms; and/or anti-aging. The Bifidobacterium longum subsp. infantis preferably comprises a strain having the accession number CGMCC No. 21109.
Half of the dyads will be randomized to participant in the Chicago Parent Program (CPP), an evidence-based parenting preventive intervention for urban poor parents with children between the ages of 2-8 with behavior problems. The Chicago Parent Program consists of 12 groups sessions (11 weekly, 1 booster session). The groups are co-facilitated by two certified group leaders. Parents learn positive parenting and effective child behavior management skills, strategies to support the child's attention, literacy, and social skills, and stress management and problem solving techniques. Skill building is accomplished through watching videos of real-life parents and children during parent-child interactions, group discussion, role-playing, and weekly homework assignments.
In Upper cross syndrome upper trapezius, pectoralis major, and levator scapulae become tight and rhomboids , serratus anterior, middle and lower trapezius, and deep neck flexors, including scalene becomes weak. The postural muscles have tendency to become tight while the phasic muscles have tendency to become weak and inhibited. Thus typical pattern of altered posture and muscular imbalance occurs whenever dysfunction of muscle start. mainly muscular imbalance between weak and tonic muscles leads toward this upper cross syndrome. Soft tissue and cervical spine disorders are found out to be the major contributor in neck pain but when postural abnormality becomes the reason behind neck ache than this is categorized as Upper cross syndrome due to this imbalance in muscles our body has to suffer from severe consequences.rounded shoulder posture is a result of protracted girdle of shoulder due to muscular imbalances between agonist and antagonist muscles resulting in extreme pain and exaggerated cervical curvature.Imbalanced stress on cervical vertebrae is responsible in creating extra pull on neck and head similarly change in normal posture is responsible in overloading, weakening or tightening of cervical area. Characteristics of patient presenting with UCS will have forward head posture, kyphosis ,hunch of thoracic spine (rounded shoulder),winged scapulae, protracted and elevated shoulder and reduced thoracic spine mobility. UCS with the passage of time can detoriate persons physical fitness and health ,it is not only responsible for changes in posture of upper back i.e hypokyphosis over time, but it is also responsible for inducing respiratory problems including asthma. It also cause neck back shoulder and chest wall pain, this pain can be caused by muscular imbalance leading to overuse and fatigue of muscle because of movement dysfunction of back and neck.when muscles become fatigued they start generating more amount of inflammatory chemicals resulting in becoming more sore and increased spasticity. With the passage of time biomechanical and postural changing will induce osteoarthritis in upper thoracic and lower cervical spine in early ages. Functional Shoulder impingement syndrome is also considered to be another complication of Upper cross syndrome. Therefore it is necessary to correctly diagnose and treat this condition before its complication starts worsening.
Accurately distinguishing HER2-2+ tumors from HER2-0/1+ tumors via immunohistochemistry (IHC) is still very challenging. HER2 IHC 2+ is considered to indicate moderate expression and is easier to distinguish, with more reliable results in previous and current clinical practice. We focused on HER2-2+ patients and evaluated the switch in HER2 status between primary and paired recurrent disease patients to evaluate the discordance of HER2-2+ expression. We included patients who were HER2-2+ of primary or rebiopsy tumor samples, to evaluate the evolution of HER2-2+ expression. In the cohort with a total of 159 patients with HER2-2+ expression in either primary tumor or locoregional/distant metastasis samples, 44.0% had HER2-2+ in primary tumor and 88.8% in recurrent disease. Among patients with primary and recurrent HER2-2+ breast cancers, 18.5% and 15.2% of the patients, respectively, had HER2 gene amplification via ISH. The overall rate of discordance in HER2 IHC results was 67.1%. Among primary HER2-2+ patients, 74.6% were maintained in the HER2-2+ cohort at the recurrence. The discordance was mostly driven by patients switching from HER2-2+ to HER2-1+ (64.7%). Among HER2-2+ recurrent patients, discordance in the IHC results was mostly driven by switching from HER2-0 to HER2-2+ (47.1%). When HER2-low was added to the analysis, the overall rate of HER2 discordance was 40.4%. The proportion of patients with discordant HER2 expression was significantly greater among HR-positive patients than negative patients (44.1% vs. 21.7%, p=0.062). HER2 expression in primary and recurrent breast cancer samples was highly unstable. Discordance was more frequently observed in the HR-positive population.
Currently, to overcome the short half-life of the local anesthetic ropivacaine, drug delivery systems such as nanoparticles and liposomes have been used to prolong the analgesic effect, but they are prone to abrupt release from the site of administration or have poor slow-release effects, which increases the risk of cardiotoxicity. In this study, injectable lipid suspensions based on ropivacaine-docusate sodium hydrophobic ion pairing (HIP) were designed to significantly prolong the duration of analgesia. The resulting ion-paired lipid suspension (HIP/LIPO) had a micrometer scale and a high zeta potential, which facilitates stable in situ retention. The strong interaction between docusate sodium and ropivacaine was verified using thermal and spectroscopic analyses, and the formation of micron-sized polymorphic vesicles was attributed to the mutual stabilizing interactions between ropivacaine-docusate sodium HIP, docusate sodium and lecithin. The HIP/LIPO delivery system could maintain drug release for more than 5 days in vitro and achieve high analgesic efficacy for more than 10 days in vivo, reducing the side effects associated with high drug doses. The stable HIP/LIPO delivery system is a promising strategy that offers a clinically beneficial alternative for postoperative pain management and other diseases.
IBI110 and sintilimab will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks) for 3 cycles during the neoadjuvant treatment phase. IBI110 and sintilimab will be administered as IV infusion 3 weeks during the post-operative adjuvant phase up to 1 year.
Pancreatic cancer is one of the few cancers whose survival rate has not improved significantly due to high local recurrence and systemic metastasis despite advances in diagnosis and treatment over the past 40 years. And currently pancreatic cancer is the fifth leading cause of cancer-related death in Korea. For this reason, various anti-cancer therapies and radiotherapy have been tested to improve survival.

Due to recent advances in radiotherapy technology, proton beam therapy (PBT) is a promising treatment for pancreatic cancer because it can reduce radiation dose from surrounding normal tissue while maximizing radiation to tumor tissues due to the distinct physical properties of proton beam. Low toxicity have been reported. In addition, retrospective analysis of pancreatic cancer patients (n=37) who performed proton therapy (PBT) from June 2013 to July 2016 showed promising therapeutic performance and less toxicity (survival rate, 19.3 months; Grade ≥ 3 Toxicity, 0%). In addition, gene polymorphisms of several genes (CD44, CD166, XAF1, MMP9, MUC1/4, SMAD7, SMAD4 (DPC), RRM1, ERCC1, HER2, etc.) in pancreatic cancer have been reported to be associated with recurrence and prognosis. Therefore, in this study, a prospective cohort of pancreatic cancer patients treated with proton beam therapy was established to analyze local control, survival, recurrence, toxicity, proton treatment plan information, gene expression information to analyze local control (LC), overall survival (OS), recurrence-free surival (RFS), and factors predicting treatment-related toxicity.